CSL's Breakthrough: New Monthly Injectable Andembry Approved for Hereditary Angioedema
Key Insights
Australian regulators have approved Andembry, a novel engineered antibody treatment developed by CSL (search) in Melbourne, offering new hope for hereditary angioedema (search) patients.
Clinical trials demonstrated remarkable efficacy, with Andembry reducing attack frequency by 87% over six months and completely preventing attacks in 62% of treated patients.
The precision treatment, requiring only one monthly self-administered injection, represents a significant improvement over current twice-weekly plasma-derived treatments.
In a significant advancement for rare disease treatment, Australian regulators have approved Andembry, a groundbreaking engineered antibody therapy developed by CSL (search) for hereditary angioedema (search) (HAE). The Melbourne-developed treatment promises to transform the management of this potentially fatal genetic condition that affects approximately one in 50,000 people.
Understanding the Disease Burden
Hereditary angioedema (search) manifests as sudden, severe swelling episodes that can affect various body parts, including potentially fatal throat swelling. Between 2006 and 2013, the condition claimed 26 Australian lives. The disease stems from a genetic mutation affecting the C1I (search) protein, crucial for regulating immune and inflammatory responses. Without proper C1I function, routine triggers such as stress, physical contact, or hormonal changes can initiate uncontrolled swelling attacks.
Revolutionary Scientific Approach
Dr. Con Panousis, CSL (search)'s vice-president of research, explains the breakthrough: "With an antibody's exquisite sensitivity, we can engineer it to be really potent." The development process, initiated in 2009, combined advanced computer simulations with laboratory experimentation. Dr. Veronika Rayzman led the screening of hundreds of engineered antibodies from CSL's vast database to identify optimal candidates.
Through precise engineering and optimization, the research team achieved a remarkable thousand-fold increase in the antibody's potency. This enhancement enables a simplified dosing regimen of just one self-administered injection monthly, compared to the current standard of twice-weekly plasma-derived C1I (search) treatments.
Compelling Clinical Evidence
The efficacy of Andembry was definitively demonstrated in a randomized controlled trial, with results published in The Lancet in 2023. Key findings include:
- 87% reduction in attack frequency over six months
- Average monthly attacks decreased from 2.0 to 0.27
- 62% of treated patients remained attack-free throughout the study
- Safety profile comparable to placebo
Manufacturing and Access
The drug will be manufactured at CSL (search)'s Broadmeadows facility, maintaining Australia's position in advanced pharmaceutical production. The treatment has been recommended for government subsidy, potentially ensuring broader access for patients.
Dr. Helen Cao, who conducted the animal studies, reflects on the achievement: "I was so surprised. It was so effective. I have been in research over 35 years, worked on several projects, tested several drugs. This is the first one that has been approved to be used in patients. We're very proud. We finally hit the breakthrough."
For patients like Fiona Wardman, who experienced her first HAE attack at age seven and faced life-threatening throat swelling at 31, Andembry represents more than just a medical advancement – it offers the promise of a normal life free from the constant threat of unexpected and dangerous swelling episodes.